A scientist to lead your project, full analytical support to keep it on track, and a veteran team to complete it successfully. That’s the Metrics promise.
Metrics expands with new fast-track product development laboratory and Gerteis Mini-Pactor®.
The path to compliance for USP 232 and USP 233 elemental impurities begins with Metrics three step program.
Our experienced scientists bring a wealth of knowledge to your biggest drug development challenges. They also bring something else: leadership.
When it comes to pharmaceutical development, few CDMOs can match the depth of expertise and experience you’ll find here.
When you bring your development project to us, you’re bringing it to a finely-tuned team of scientists and technicians committed to delivering quality, on-time results.
Join us Thursday, April 30 at 2:00 p.m. EDT for a quick, 15-minute webinar as we discuss the impact of roller compaction processing parameters and resulting tableting properties of roller compacted granules.Register today
Sending a sample to Metrics?
Use this form to record your sample, storage and testing information.
Metrics Contract Services has received four CMO Leadership Awards recognizing the company’s outstanding performance. The four categories in which Metrics has won are Innovation for Big Pharma, Regulatory Track Record for Big Pharma, Innovation for Mid-Size & Specialty Pharma and Regulatory Track Record for Mid-Size & Specialty Pharma.Learn more
Metrics Contract Services has significant experience utilizing CAD technology throughout the drug development process. Let us help with your next project.Learn more
Dr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology. The U.S. Patent and Trademark Office awarded Gold a patent (No. 8,858,993) for his application, “Coated tablets with zero-order or near zero-order release kinetics.”Learn more
In a feature about analytical testing, Chris Golebiowski, vice president of analytical services, discusses the new USP testing guidelines coming in December 2015.Read article
Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract servicesLearn more
Benefits of this new proprietary technology include improved and consistent drug absorption.Learn more
Metrics Inc. now offers proprietary pellet technologies enabling controlled release to help support therapeutic effectiveness of active pharmaceutical ingredients (API).Learn more
Joe Cobb and his team used the principles of QbD to improve the robustness of a core tablet for a novel modified release oral solid dosage form. View the AAPS 2012 poster and watch a short video about how Metrics applies the principles of QbD to solve formulation development issues.Read Poster